Eupraxia Pharmaceuticals Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
EPRX Nasdaq 2834 www.eupraxiapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences - Apr 13th, 2026 6:00 am
New Strong Sell Stocks for April 2nd - Apr 2nd, 2026 4:03 am
Eupraxia Reports Positive Six-Month Data From Eosinophilic Esophagitis Trial - Mar 17th, 2026 5:38 am
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis - Mar 17th, 2026 5:00 am
Eupraxia Pharmaceuticals Q4 Loss Widens - Mar 13th, 2026 5:19 am
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results - Mar 12th, 2026 7:03 pm
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option - Feb 20th, 2026 1:38 pm
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option - Feb 20th, 2026 1:10 pm
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering - Feb 19th, 2026 5:28 am
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants - Feb 19th, 2026 12:18 am
Eupraxia Pharmaceuticals Announces Proposed Public Offering - Feb 18th, 2026 2:01 pm
Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation - Feb 5th, 2026 10:06 am
Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial - Jan 8th, 2026 7:49 am
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy - Jan 8th, 2026 5:34 am
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors - Dec 16th, 2025 8:00 am
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here’s Why - Dec 4th, 2025 8:09 pm
Individual investors account for 43% of Eupraxia Pharmaceuticals Inc.'s (TSE:EPRX) ownership, while institutions account for 26% - Nov 17th, 2025 3:37 am
Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet - Nov 14th, 2025 7:55 am
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI - Nov 13th, 2025 3:00 pm
Eupraxia Pharmaceuticals Posts Wider Q3 Loss, Has Sufficient Cash on Hand To Fund It Into H1 2028 - Nov 4th, 2025 3:10 pm